Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
- Resource Type
- Article
- Source
- In
Clinical Breast Cancer December 2014 14(6):405-412 - Subject
- Language
- ISSN
- 1526-8209